HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis.

Sung Soo ParkGi June MinSung-Soo ParkSilvia ParkSung-Eun LeeByung-Sik ChoYoo-Jin KimSeok LeeHee-Je KimChang-Ki MinSeok-Goo ChoJong Wook LeeKi-Seong Eom

Published in: Therapeutic advances in hematology (2020)

RIC allo-HCT can be a valid choice providing graft-versus-fibrosis effect for advanced MF patients. However, HLA-mismatched donor and high pre-HCT ferritin level related to fatal hepatic GVHD should be regarded as poor-risk parameters.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
stem cell transplantation
peritoneal dialysis
bone marrow
prognostic factors
cell death
low dose
patient reported outcomes
high dose
cell cycle arrest
allogeneic hematopoietic stem cell transplantation
decision making